3 stocks from the healthcare sector that are at their lows over the past year
The year 2023 was not an easy one for the healthcare sector and was full of challenges. While other sectors were achieving record returns and rapid growth, healthcare stocks faced uncertainty and stagnation. Here are three healthcare stocks with growth potential that may be interesting opportunities for investors this year.
After a challenging 2023, which brought many challenges and uncertainty, investors are looking ahead to what 2024 will bring. New technological innovations, regulatory changes and shifts in healthcare are creating new investment opportunities and bringing hope for growth in the sector.
Pfizer $PFE+3.4%
Pharmaceutical giant Pfizer has been struggling with its share price decline, which may present an opportunity for investors. Despite a challenging 2023, the company maintains its position in the healthcare sector and offers hope for for future growth. With its significant research and drug development for COVID-19 Pfizer has the potential to increase its revenues and profits in the coming period.
Pfizer is not just a vaccine company, it is known for its research and development of drugs for a wide range of diseases, including cancer. The company also has robust revenues from patented drugs, which contribute to thelong-term stability of its business model.
Despite itslow stock price, the company is still considered one of the largest and most trusted healthcare companies in the world. Investors looking for long-term growth and stability should consider investing in$PFE+3.4% stock .
Pfizer
PFE
Pfizer
PFE3. Bristol-Myers Squibb $BMY+11.4%
Bristol-Myers Squibb is another major healthcare company that offers stable earnings and dividends for investors. Despite the stock price decline in 2023, the the company is holding its ground in the market and has the potential to increase its revenue and earningsy in the period ahead.
Bristol-Myers Squibb is known for its portfolio of drugs in the areas of oncology, cardiovascular disease and immunology. The company has a long history of innovation and research that supports the long-term stability of its revenues and earnings.
Despite short-term challenges, the company has growth and dividend yield potential. Investors looking for stable and long-term investment opportunities in the healthcare sector may see potential and an interesting opportunity in this company.
Ginkgo Bioworks $DNA+10.0%
Ginkgo Bioworks specializes in Biotechnology research and innovation. Its recent collaboration with Pfizer brings new opportunities for the development of innovative drugs and therapeutics. While the company is facing revenue challenges, it has long-term potential to become a key player in the biotechnology sector.
Ginkgo Bioworks focuses on using "synthetic biology" to create new products and technologies in the healthcare, industrial and agricultural sectors. The company works with a wide range of partners, including pharmaceutical companies, to develop innovative drugs and solutions for today's healthcare challenges.
Despite short-term challenges, the company has long-term potential for growth and innovation in biotechnology. Investors seeking opportunities to invest in innovative and fast-growing companies, this company could be an interesting choice.
Disclaimer: There is a lot of inspiration to be found on Bulios, however, stock selection and portfolio construction is up to you, so always do a thorough analysis of your own.
Source.